Shanghai Fosun Pharmaceutical (Group) Co (HK:2196) has released an update.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has announced proposed amendments to its Articles of Association and related appendices, in response to recent legislative and regulatory changes in China, including the new Company Law and guidelines from the China Securities Regulatory Commission. These amendments, which do not change class meeting requirements, require shareholder approval at an upcoming extraordinary general meeting. Shareholders will receive details on the amendments and meeting notification in a forthcoming circular.
For further insights into HK:2196 stock, check out TipRanks’ Stock Analysis page.
